Advancing Global Health

Gilead recognizes that the development of innovative medicines for life-threatening diseases is only one aspect of improving public health. We also invest in programs that promote prevention, strengthen healthcare infrastructure, and provide education and financial support to the most vulnerable communities around the world.

By enabling access to medicines, challenging assumptions, fighting stigma and collaborating with partners worldwide, we work not simply to treat some of the world’s most challenging public health threats – but to eliminate them.


50,000-90,000 new cases occur each year, but only 25-45% are reported

Gilead Sciences and the WHO Tackle VL in Southeast Asia

Visceral leishmaniasis (VL) is a parasitic disease. An estimated 50,000 to 90,000 new cases occur worldwide each year, but it is estimated that only 25-45% of those cases are reported. VL is almost always fatal if untreated. We are collaborating with the World Health Organization (WHO) to provide treatment free of charge to all people diagnosed with the disease.


Italy’s First HIV/HCV Support Center for LGBTQ+ Population

BLQ Checkpoint in Bologna, Italy – supported by Gilead – is the country’s first and only community HIV and HCV testing center for members of the LGBTQ+ community. In addition to testing services, the organization offers support, counseling, education and a comfortable environment.

Italy’s First HIV/HCV Support Center for LGBTQ+ Population

Keeping Girls and Young Women HIV-Free in Sub-Saharan Countries

Keeping Girls and Young Women HIV-Free in Sub-Saharan Countries

Gilead partners with the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) to help reduce HIV in adolescent girls and young women in 10 sub-Saharan African countries.


The Contribution to the Elimination of Hepatitis C in Italy and Around the World

The WHO has set the goal of eliminating viral hepatitis worldwide by 2030. Through awareness, screening and care, we’re helping governments, patients and payers in efforts to eliminate the chronic hepatitis C virus (HCV) and end the disease.

In Italy, at the request of scientific societies and the EpaC Patients Association and in collaboration with AIFA, Gilead has provided the National Health Service with 12-week complete therapies for adolescents. Since 2018, Gilead has donated, free of charge, medicines to treat adolescents aged 12 to 18 with hepatitis C at medical centers identified by the Italian Society of Pediatrics and by AIFA.